Skip to main content
Log in

The Prognostic Value of Serum Creatinine on Admission in Fibrinolytic-Eligible Patients with Acute Myocardial Infarction

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Background: Previous studies have demonstrated that impaired renal function is associated with unfavourable outcomes in patients with acute coronary syndromes and following percutaneous coronary intervention.

Methods: We hypothesized that serum creatinine (Cr) on admission is a useful predictor of mortality in fibrinolytic-eligible patients with ST-elevation myocardial infarction (MI). Data were collected from 352 patients with ST-elevation MI, 89% of patients underwent early invasive management.

Results: 30-day and 6-month mortality were increased among patients with mild to moderate (Cr > 1.2–2.8 mg/dl) renal dysfunction compared to patients with normal (Cr ≤ 1.2 mg/dl) renal function (3.4% vs. 16.1%, p < 0.001 and 4.5% vs. 19.5%, p < 0.001). After adjustment for previously identified correlates of mortality in a multiple logistic regression model, higher Cr on admission remained independently associated with increased mortality (30-day, OR 4.78, 95%CI 1.55–14.73, p = 0.006; 6-month, 3.82 (1.45–10.11), p = 0.007). The incidence of mortality was reduced among those patients with renal dysfunction that also underwent acute percutaneous coronary intervention [30-day, OR 0.13, 95%CI 0.02–1.06, p < 0.03; 6-month, 0.23 (0.05–1.07), p < 0.05].

Conclusion: Cr on admission is a strong and independent predictor of mortality in patients with ST-elevation MI. This association does not appear to be mediated by reduced fibrinolytic efficacy, or by higher reinfarction rates among patients with renal dysfunction. Cr on admission is a rapid and widely available marker to identify high-risk patients with ST-elevation MI that have additional improvements in survival when treated with percutaneous coronary intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on longterm dialysis. N Engl J Med 1998;339:799-805.

    Google Scholar 

  2. Al Suwaidi J, Reddan DN, Williams K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002;106:974-980.

    Google Scholar 

  3. Luft FC. Renal disease as a risk factor for cardiovascular disease. Basic Res Cardiol 2000;95:I72-I76.

    Google Scholar 

  4. Asinger RW, Henry TD, Herzog CA, et al. Clinical outcomes of PTCA in chronic renal failure: a case-control study for comorbid features and evaluation of dialysis dependence. J Invasive Cardiol 2001;13:21-28.

    Google Scholar 

  5. Vaitkus PT. Current status of prevention, diagnosis, and management of coronary artery disease in patients with kidney failure. Am Heart J 2000;139:1000-1008.

    Google Scholar 

  6. Rubenstein MH, Harrell LC, Sheynberg BV, et al. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 2000;102:2966-2972.

    Google Scholar 

  7. Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002;39:1113-1119.

    Google Scholar 

  8. Januzzi JL, Cannon CP, DiBattiste PM, et al. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). Am J Cardiol 2002;90:1246-1249.

    Google Scholar 

  9. Rao V, Weisel RD, Buth KJ, et al. Coronary artery bypass grafting in patients with non-dialysis-dependent renal insufficiency. Circulation 1997;96:II-38-43; discussion II-44-45.

    Google Scholar 

  10. Liu JY, Birkmeyer NJ, Sanders JH, et al. Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation 2000;102:2973-2977.

    Google Scholar 

  11. Anderson RJ, O'Brien M, MaWhinney S, et al. Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery. VA cooperative study #5. Kidney Int 1999;55:1057-1062.

    Google Scholar 

  12. Hirose H, Amano A, Takahashi A, Nagano N. Coronary artery bypass grafting for patients with non-dialysisdependent renal dysfunction (serum creatinine > or = 2.0 mg/dl). Eur J Cardiothorac Surg 2001;20:565-572.

    Google Scholar 

  13. Nakayama Y, Sakata R, Ura M, Itoh T. Long-term results of coronary artery bypass grafting in patients with renal insufficiency. Ann Thorac Surg 2003;75:496-500.

    Google Scholar 

  14. Luke RG. Chronic renal failure: a vasculopathic state. N Engl J Med 1998;339:841-843.

    Google Scholar 

  15. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002;137:563-570.

    Google Scholar 

  16. Beatti JN, Soman SS, Sandberg KR, et al. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis 2001;37:1191- 1200.

    Google Scholar 

  17. McCullough PA, Sandberg KR, Borzak S, et al. Benefits of aspirin and beta-blockade in patients with chronic kidney disease. Am Heart J 2002;144:226-232.

    Google Scholar 

  18. Hillege HL, van Gilst WH, van Veldhuisen DJ, et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: theCATS randomized trial. Eur Heart J 2003;24:412-420.

    Google Scholar 

  19. Shlipak MG, Heidenreich PA, Noguchi H, et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002;137:555-562.

    Google Scholar 

  20. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J AmColl Cardiol 2003;42:201-208.

    Google Scholar 

  21. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20.

    Google Scholar 

  22. PCAT Collaborators. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J. 2003;145:47-57.

    Google Scholar 

  23. Keeley EC, McCullough PA. Coronary revascularization in patients with end-stage renal disease: risks, benefits, and optimal strategies. Rev Cardiovasc Med 2003;4:125-130.

    Google Scholar 

  24. Keeley EC, Kadakia R, Soman S, McCullough PA. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. Am J Cardiol 2003;92:509-514.

    Google Scholar 

  25. Neuhaus KL, Molhoek GP, Zeymer U, et al. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4. Am Coll Cardiol 1999;34:966-973.

    Google Scholar 

  26. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs. accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J. 2000;21:2005-2013.

    Google Scholar 

  27. Topol EJ, GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-1914.

    Google Scholar 

  28. Brener SJ, Zeymer U, Adgey AA, et al. Eptifibatide and lowdose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol 2002;39:377-386.

    Google Scholar 

  29. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen(ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605-613.

  30. Charbonnier B, Pluta W, De Ferrari G, et al. Evaluation of two weight-adjusted single bolus doses of amediplase to patients with acute myocardial infarction: The 3K2 trial. Circulation 2001;104:II-538.

    Google Scholar 

  31. Giugliano RP, Roe MT, Harrington RA, et al, on behalf of the INTEGRITI Investigators. Combination reperfusion therapy with eptifibatide and reduced dose tenecteplase for ST-elevation myocardial infarction: Results of Integrilin_R and tenecteplase in acute myocardial infarction (INTEGRITI) phase II angiographic trial. J Am Coll Cardiol 2003;41:1251-1260ii.

    Google Scholar 

  32. Hobbach HP, Giugliano RP, Pfeiffer P, et al. Efficacy and safety of an adjunctive treatment with clopidogrel in patients pretreated with combination thrombolytic therapy. Z Kardiol 2003;92:I/328.

    Google Scholar 

  33. Hobbach HP, Gibson CM, Giugliano RP, et al. A new dosing regimen of tirofiban in combination with half-dose tenecteplase in acute myocardial infarction. Eur Heart J 2003;24:546.

    Google Scholar 

  34. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of 174 Hobbach et al. infarcting myocardium early II trial substudy. Circulation 2000;102:2031-2037.

    Google Scholar 

  35. The Thrombolysis in Myocardial Infarction (TIMI) triala. Phase I findings. TIMI Study Group. N Engl J med. 1985;312:932-936.

    Google Scholar 

  36. Gibson CM, Pinto DS, Murphy SA, et al. for the TIMI Study Group. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003;42:1535- 1543.

    Google Scholar 

  37. Wolfe RA, Port FK, Webb RL, et al. Experts from the united states renal data system, 1998 annual report: V. Patients mortality and survival. Am J Kidney Dis 1998;32:I69-I80.

    Google Scholar 

  38. Shlipak MG, Fried LF, Crump C, et al. Elevations of in-flammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003;107:87-92.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hobbach, HP., Gibson, C.M., Giugliano, R.P. et al. The Prognostic Value of Serum Creatinine on Admission in Fibrinolytic-Eligible Patients with Acute Myocardial Infarction. J Thromb Thrombolysis 16, 167–174 (2003). https://doi.org/10.1023/B:THRO.0000024055.13207.50

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:THRO.0000024055.13207.50

Navigation